Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RUNX1 | Q01196 | 7/20 | 0.68 |
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
| ▸ | CBFB | Q13951 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 2/20 | 0.39 |
| ▸ | BCR | P11274 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17525971 | 0.92 | RUNX1 (0.70) | RUNX1ACHECBFBLTA4HFGFR1 | |
| SCHEMBL17525974 | 0.92 | RUNX1 (0.69) | RUNX1ACHECBFBLTA4HDRD2 | |
| SCHEMBL17525979 | 0.91 | RUNX1 (0.71) | RUNX1ACHECBFBDRD2DRD3 | |
| SCHEMBL17525947 | 0.88 | RUNX1 (0.62) | RUNX1CBFB | |
| SCHEMBL17525959 | 0.87 | RUNX1 (0.88) | RUNX1ACHECBFBDRD2DRD3 | |
| SCHEMBL17525972 | 0.85 | RUNX1 (0.86) | RUNX1ACHECBFBLTA4HKDR | |
| SCHEMBL17525977 | 0.84 | RUNX1 (0.68) | RUNX1DRD2DRD3 | |
| SCHEMBL17525965 | 0.84 | RUNX1 (0.87) | RUNX1ACHECBFBLTA4HKDR | |
| SCHEMBL17525978 | 0.83 | RUNX1 (0.63) | RUNX1CBFBDRD2DRD3 | |
| SCHEMBL17525964 | 0.82 | RUNX1 (0.83) | RUNX1CBFB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230277454-A1 | NANO-EMULSION OF CBFß-RUNX1 INHIBITOR FOR OCULAR DRUG DELIVER | MASSACHUSETTS EYE AND EAR INFIRMARY | 2023-09-07 | — | — | US | disclosed |
| US-11739326-B2 | RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2023-08-29 | — | — | US | disclosed |
| US-11583497-B2 | Nano-emulsion of CBFß-RUNX1 inhibitor for ocular drug delivery | THE SCHEPENS EYE RESEARCH INSTITUTE, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20220184109-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ABERRANT ANGIOGENESIS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2022-06-16 | — | — | US | disclosed |
| US-11229662-B2 | Compositions and methods for the treatment of aberrant angiogenesis | THE SCHEPENS EYE RESEARCH INSTITUTE, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| EP-3180004-B1 | CANCER THERAPEUTICS | UNIV VIRGINIA PATENT FOUNDATION (US) | 2021-01-06 | — | — | EP | disclosed |
| US-20200375899-A1 | NANO-EMULSION OF CBFß-RUNX1 INHIBITOR FOR OCULAR DRUG DELIVERY | MASSACHUSETTS EYE AND EAR INFIRMARY | 2020-12-03 | — | — | US | disclosed |
| US-20200377888-A1 | RUNX1 INHIBITION FOR TREATMENT OF PROLIFERATIVE VITREORETINOPATHY AND CONDITIONS ASSOCIATED WITH EPITHELIAL TO MESENCHYMAL TRANSITION | MASSACHUSETTS EYE AND EAR INFIRMARY | 2020-12-03 | — | — | US | disclosed |
| US-10562890-B2 | Cancer therapeutics | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190350961-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ABERRANT ANGIOGENESIS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2019-11-21 | — | — | US | disclosed |
| US-20170233375-A1 | CANCER THERAPEUTICS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2017-08-17 | — | — | US | disclosed |
| WO-2016025744-A1 | CANCER THERAPEUTICS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2016-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200375899-A1 | NANO-EMULSION OF CBFß-RUNX1 INHIBITOR FOR OCULAR DRUG DELIVERY | RUNX1, CBFB, IKZF1 | RUNX1 1/4885ACHE 4301/4885CBFB 2/4885 |
| US-20170233375-A1 | CANCER THERAPEUTICS | RUNX1, CBFB, MCL1 | RUNX1 1/4885ACHE 2581/4885CBFB 2/4885 |
| US-20200377888-A1 | RUNX1 INHIBITION FOR TREATMENT OF PROLIFERATIVE VITREORETINOPATHY AND CONDITIONS ASSOCIATED WITH EPITHELIAL TO MESENCHYMAL TRANSITION | RUNX1, CXCL12, MITF | RUNX1 1/4885ACHE 4885/4885CBFB 7/4885 |
| US-20190350961-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ABERRANT ANGIOGENESIS | VEGFA, PGF, FLT4 | RUNX1 183/4885ACHE 3260/4885CBFB 374/4885 |
| US-11229662-B2 | Compositions and methods for the treatment of aberrant angiogenesis | VEGFA, PGF, FLT4 | RUNX1 183/4885ACHE 3260/4885CBFB 374/4885 |
| US-11739326-B2 | RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition | RUNX1, CXCL12, MITF | RUNX1 1/4885ACHE 4885/4885CBFB 7/4885 |
| US-10562890-B2 | Cancer therapeutics | RUNX1, CBFB, MCL1 | RUNX1 1/4885ACHE 2581/4885CBFB 2/4885 |
| US-20220184109-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ABERRANT ANGIOGENESIS | VEGFA, PGF, FLT4 | RUNX1 183/4885ACHE 3260/4885CBFB 374/4885 |
| US-20230277454-A1 | NANO-EMULSION OF CBFß-RUNX1 INHIBITOR FOR OCULAR DRUG DELIVER | RUNX1, CBFB, IKZF1 | RUNX1 1/4885ACHE 4273/4885CBFB 2/4885 |
| US-11583497-B2 | Nano-emulsion of CBFß-RUNX1 inhibitor for ocular drug delivery | RUNX1, CBFB, IKZF1 | RUNX1 1/4885ACHE 4301/4885CBFB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.